BioCentury and BIA present: Company building in a COVID-19 world
As the COVID-19 crisis continues, how has the U.K.’s biotech ecosystem fared?
In this webinar, we discuss key findings from a recent BioCentury-BIA survey of U.K. biotechs.
- How much cash runway do companies have?
- Will management teams secure their target levels of financing?
- Are U.K. biotechs taking advantage of new government support packages, including the Future Fund and the Coronavirus Job Retention Scheme?
Following the discussion, BioCentury and BIA convene a special panel of U.K biotech CEOs and investors to discuss the survey, and the outlook for company building in a COVID-19 world.
Speakers will include: Simone Fishburn, Ph.D., VP & Editor in Chief, BioCentury Inc; Steve Bates, CEO, UK BioIndustry Association
Simone serves as Vice President and Editor in Chief of BioCentury, bringing experience from both industry and academia in translational science, where she focused for over 15 years on the scientific, commercial and strategic considerations for advancing laboratory discoveries to products for patients.
Since joining BioCentury in 2013, Simone has written and edited on innovation from idea to patient, most recently serving as Executive Editor. Previously, she was a director of translational research at Nektar Therapeutics and a senior managing consultant at Exponent Inc., where she specialized in projects for the biopharma industry. Simone serves as an adviser on multiple university translational programs, including initiatives at the University of California and Stanford University. Simone is also active in programs to advance women's careers; she is a board member of Women In Bio and served as its President in 2013-14.
Simone is a Fulbright scholar and performed a post-doc at the University of California San Francisco. She holds a Ph.D. in Molecular Pharmacology from the Weizmann Institute of Science, and an M.A. and B.A. in Pharmacology from Cambridge University.
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Charlotte believes in equitable access to effective therapies. She is the CEO and Co-founder of Theolytics, a pre-clinical biotechnology company harnessing viruses to combat disease and a Board Member of the UK Bioindustry Association.
Previously Co-Founder of New Medicine Partners, Charlotte has worked with organisations spanning three continents to translate novel life science technologies to the point of commercial viability; clients included government ministries, national funding bodies and world leading research institutes. Her personal interests have led her to take leadership roles within a number of organisations, including: as curator of the World Economic Forum Global Shapers network; Managing Director of HealthTech Women London; and HelloTomorrow’s London Chair for Healthcare and Medical Technologies.
Charlotte graduated as a University of Cambridge Bioscience Enterprise M.Phil Scholar and was a shortlisted finalist for Cambridge Entrepreneur of the Year. She was the youngest listed 2016 nominee for MT’s 35 under 35 Award.
Jolyon is co-founder and Head of Business Development at PetMedix, a Cambridge-based biopharmaceutical company developing antibody-based therapeutics for companion animals. PetMedix is based on Jolyon's PhD work in the laboratory of Prof Allan Bradley FRS, who is CSO and co-founder of both PetMedix and Kymab Ltd.
Balancing his studies at the University of Cambridge with an interest in start-ups and entrepreneurship, Jolyon worked with the founding team of Simprints for a year and then for Horizon Discovery in both Boston, MA and Cambridge, UK. He was named Cambridge Young Entrepreneur of the Year in 2017 and was a finalist in Onestart 2014. Jolyon is passionate about diversity and representation, and volunteers with the Good Lad Initiative - running workshops on tackling toxic masculinity in university sports teams. Jolyon was part of the first cohort of the BIA PULSE programme.
Julie joined Panmure Gordon in 2015 and has 20 years’ experience in Life Sciences research across a wide range of Healthcare subsectors. She previously worked at Canaccord Genuity, Piper Jaffray and Nomura having started her City career at Beeson Gregory, where she became Head of Lifesciences research. Julie has a PhD in Microbiology from the University of Kent and industry experience in both Europe and the US. She is also a panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.
This webinar will take place on Thursday 23 July, 16:00-17:00 BST/GMT+1 (London, UK).
This webinar is free to attend for both members and non-member of the BIA.
By registering for this event you agree to our terms & conditions:
If you have any issues registering, or have not received a link to the webinar by Thursday morning BST, please contact BIAevents@bioindustry.org.